Drugs / PRG-1801
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06519565 | Aug 2024 → Dec 2026 expected | thrombocytopenia due to immune destruction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 0 | NCT06497387 | Jul 2024 → Jul 2027 expected | immunoglobulin G4-related sclerosing disease, lupus nephritis | Tongji Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06277427 | Feb 2024 → Feb 2026 overdue | anti-neutrophil cytoplasmic antibody-associated vasculitis, lupus nephritis | Lingli Dong | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRG-1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277427 ↗ |
| Action | Deplete | “CAR T cells against BCMA may provide a novel therapeutic way for the refractory LN and ANCA-associated vasculitis patients to eliminate the pathogenic autoantibody-secreting cells” NCT06277427 ↗ |
| Modality | Cell therapy | “a novel CAR-T cell therapy using PRG-1801 cells” NCT06277427 ↗ |
| Route | Intravenous | “PRG-1801 is then administered as a single intravenous infusion” NCT06519565 ↗ |